Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • A new multipurpose on-off switch for inhibiting bacterial growth

    Researchers in Lund have discovered an antitoxin mechanism that seems to be able to neutralise hundreds of different toxins and may protect bacteria against virus attacks. The mechanism has been named Panacea, after the Greek goddess of medicine whose name has become synonymous with universal cure. The understanding of bacterial toxin and antitoxin mechanisms will be crucial for the future success of so-called phage therapy for the treatment of antibiotic resistance infections, the researchers say. The study has been published in PNAS.

  • A Microbial Compound in the Gut Leads to Anxious Behaviors in Mice

    A Caltech-led team of researchers has discovered that a small-molecule metabolite, produced by bacteria that reside in the mouse gut, can travel to the brain and alter the function of brain cells, leading to increased anxiety in mice. The work helps uncover a molecular explanation for recent observations that gut microbiome changes are associated with complex emotional behaviors.

  • Robots that can check your blood pressure, Researchers

    Based on the intricacies of origami and inspired by the movements of nature’s leeches his research is advancing how robots could carry out basic health care tasks in certain conditions, including in remote regions, or where minimal personal contact is needed, such as during pandemics. The research is published in the journal npj Flexible Electronics from Nature Publishing Group.

  • Decreased serum vitamin B12 level associated with narcolepsy

    Decreased serum vitamin B12 levels are independently associated with the development of narcolepsy, a sleep disorder, said recent research. The novel study illustrates the complex relationship between vitamin B12 and narcolepsy.

  • Pharma R&D pipeline and New product launches reach record level in 2021

    Biopharmaceutical R&D continued at a record breaking pace in 2021 despite the COVID-19 pandemic, according to a new report, Global Trends in R&D Overview Through 2021, by the IQVIA Institute for Human Data Science. The data show 5,500 new planned clinical trial starts occurred last year, a 14 percent increase over 2020.

  • Zydus gets 180 days shared exclusivity for Roflumilast Tablets

    The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to become a global life-sciences company transforming lives through pathbreaking discoveries.

  • Use of Copper IUD can be risky during pregnancy

    Researchers from China found out in their recent study that use of Copper Intrauterine devices can be risky during pregnancy and it could compromise embryonic development.

    Generally, IUDs (Intrauterine devices) are used to avoid pregnancy by women. But Women who use IUDs may become pregnant, albeit rarely, and many such women continue to use IUDs. Because it is difficult to remove or it may cause miscarriage.

  • Organization and Leadership in a BANI World delivered by Hindustan Unilever Chairman

    The 7th Udai Pareek Memorial Oration was delivered virtually by Mr. Sanjiv Mehta, Chairman & MD, Hindustan Unilever Ltd. (HUL), on a current subject; of Organization and Leadership in a BANI World. The lecture was presided over by Padmavibhushan Dr. Raghunath Anant Mashelkar, National Research Professor and Chairman of the National Innovation Foundation.

  • WHO grants prequalification of tocilizumab for patients with severe or critical COVID-19

    Roche announced that Actemra/RoActemra (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. It helps procurers in low- and middle-income countries identify priority medicines to improve access to care and support better health.

  • Merck joins with artificial intelligence company, Quris for Clinical Safety Prediction

    Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced it has signed an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, allowing Merck KGaA, Darmstadt, Germany to assess Quris’ BioAI safety prediction platform, comparing it to traditional in vitro and in vivo approaches.

Subscribe to Pharma News